tradingkey.logo

Amphastar Pharmaceuticals Inc

AMPH
View Detailed Chart
27.120USD
+0.310+1.16%
Close 12/26, 16:00ETQuotes delayed by 15 min
1.26BMarket Cap
11.50P/E TTM

Amphastar Pharmaceuticals Inc

27.120
+0.310+1.16%
Intraday
1m
30m
1h
D
W
M
D

Today

+1.16%

5 Days

+1.95%

1 Month

-0.88%

6 Months

+17.00%

Year to Date

-26.96%

1 Year

-28.95%

View Detailed Chart

Key Insights

Amphastar Pharmaceuticals Inc's fundamentals are relatively healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 30/158 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 31.71.In the medium term, the stock price is expected to remain stable.Despite an average stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Amphastar Pharmaceuticals Inc's Score

Industry at a Glance

Industry Ranking
30 / 158
Overall Ranking
86 / 4563
Industry
Pharmaceuticals

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score
Previous score

Analyst Rating

Based on 6 analysts
Buy
Current Rating
31.714
Target Price
+21.93%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Amphastar Pharmaceuticals Inc Highlights

StrengthsRisks
Amphastar Pharmaceuticals, Inc. is a biopharmaceutical company that focuses primarily on developing, manufacturing, marketing, and selling generic and proprietary injectable, inhalation, and intranasal products. Additionally, it sells insulin API products. Most of its finished products are used in hospital or urgent care clinical settings and are primarily contracted and distributed through group purchasing organizations and drug wholesalers. The Company manufactures and sells over 25 products, such as BAQSIMI (glucagon) nasal powder 3mg, Primatene MIST, Glucagon for Injection Emergency Kit, Enoxaparin, Naloxone and Other Marketed Products, including Cortrosyn (cosyntropin for injection), Amphadase, Epinephrine injection, Lidocaine jelly, Lidocaine topical solution, Phytonadione injection, and others. The Company manufactures and sells two API products, Recombinant Human Insulin (RHI API) and porcine insulin API, for the injectable insulin market.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 46.69% year-on-year.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 731.97M.
Fairly Valued
The company’s latest PE is 11.50, at a medium 3-year percentile range.
Institutional Buying
The latest institutional holdings are 33.97M shares, increasing 0.05% quarter-over-quarter.
Held by HACAX
Star Investor HACAX holds 276.00 shares of this stock.

Amphastar Pharmaceuticals Inc News

More news coming soon, stay tuned...

Financial Indicators

EPS

Relevant data have not been disclosed by the company yet.

Total revenue

Relevant data have not been disclosed by the company yet.

Amphastar Pharmaceuticals Inc Info

Amphastar Pharmaceuticals, Inc. is a biopharmaceutical company that focuses primarily on developing, manufacturing, marketing, and selling generic and proprietary injectable, inhalation, and intranasal products. Additionally, it sells insulin API products. Most of its finished products are used in hospital or urgent care clinical settings and are primarily contracted and distributed through group purchasing organizations and drug wholesalers. The Company manufactures and sells over 25 products, such as BAQSIMI (glucagon) nasal powder 3mg, Primatene MIST, Glucagon for Injection Emergency Kit, Enoxaparin, Naloxone and Other Marketed Products, including Cortrosyn (cosyntropin for injection), Amphadase, Epinephrine injection, Lidocaine jelly, Lidocaine topical solution, Phytonadione injection, and others. The Company manufactures and sells two API products, Recombinant Human Insulin (RHI API) and porcine insulin API, for the injectable insulin market.
Ticker SymbolAMPH
CompanyAmphastar Pharmaceuticals Inc
CEOZhang (Yongfeng Yongfeng)
Websitehttps://amphastar.com/

FAQs

What is the current price of Amphastar Pharmaceuticals Inc (AMPH)?

The current price of Amphastar Pharmaceuticals Inc (AMPH) is 27.120.

What is the symbol of Amphastar Pharmaceuticals Inc?

The ticker symbol of Amphastar Pharmaceuticals Inc is AMPH.

What is the 52-week high of Amphastar Pharmaceuticals Inc?

The 52-week high of Amphastar Pharmaceuticals Inc is 39.010.

What is the 52-week low of Amphastar Pharmaceuticals Inc?

The 52-week low of Amphastar Pharmaceuticals Inc is 20.385.

What is the market capitalization of Amphastar Pharmaceuticals Inc?

The market capitalization of Amphastar Pharmaceuticals Inc is 1.26B.

What is the net income of Amphastar Pharmaceuticals Inc?

The net income of Amphastar Pharmaceuticals Inc is 159.52M.

Is Amphastar Pharmaceuticals Inc (AMPH) currently rated as Buy, Hold, or Sell?

According to analysts, Amphastar Pharmaceuticals Inc (AMPH) has an overall rating of Buy, with a price target of 31.714.

What is the Earnings Per Share (EPS TTM) of Amphastar Pharmaceuticals Inc (AMPH)?

The Earnings Per Share (EPS TTM) of Amphastar Pharmaceuticals Inc (AMPH) is 2.358.
KeyAI